Soley
South San Francisco, US · Delaware corporation · 2 known investors
Soley Therapeutics develops proprietary imaging, AI, and automation technology to analyze cellular responses to stress and drug exposure, enabling the discovery of novel medicines and therapeutic mechanisms.
Founders & leadership
KA
Kurosh AmeriDirector
YY
Yerem YeghiazariansDirector
KV
Ken V. AlwynChief Financial Officer
Investors · 2
Competitors · 7
by search overlapSolu28 shared keywords
PatSnap24 shared keywordsPatsnap builds an AI-powered platform for R&D, IP, and innovation intelligence, offering tools for patent search, novelty and FTO analysis, patent drafting, and materials and pharma research. It serves R&D leaders, IP professionals, engineers, and scientists across industries including materials, manufacturing, life sciences, pharmaceuticals, and consumer goods.
Cowles_Investments_StemCentrx23 shared keywordsFierce Biotech is a news publication covering the biotechnology, pharmaceutical, and medtech industries, reporting on clinical trials, deals, venture capital, drug development, and research. It serves industry professionals through articles, special reports, events, webinars, and podcasts.
Applied Therapeutics17 shared keywords
Endpoints14 shared keywords
multi-step chains12 shared keywords
Kite Pharma12 shared keywords
Companies competing with Soley for the same Google search keywords, organic and paid, via search-intersection analysis.
Reported raises · per SEC filings
Form D private placements▶$20MraisedDec 2020 · 32 investors · BiotechnologyRule 506(b)
▶$20MraisedDec 2020 · 32 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kurosh AmeriDirector
- Yerem YeghiazariansDirector
- Ken V. AlwynExecutive Officer, Director
- Offering amount
- $20M
- Amount sold
- $20M
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.